Immucor, Inc.
(Nasdaq: BLUD), a global leader in providing automated instrument-reagent
systems to the blood transfusion industry, announced that on Friday, March
16, 2007, the company submitted the 510(k) premarket notification
submission for its Galileo(R) Echo(TM) instrument to the U.S. Food and Drug
Administration.
Commenting on the submission Dr. Gioacchino De Chirico, President and
CEO stated “We are very pleased to have filed this submission and look
forward to selling the instrument in the United States upon receiving FDA
clearance.”
Founded in 1982, Immucor manufactures and sells a complete line of
reagents and systems used by hospitals, reference laboratories and donor
centers to detect and identify certain properties of the cell and serum
components of blood prior to transfusion. Immucor markets a complete family
of automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at
immucor.
Statements contained in this press release that are not statements of
historical fact are “forward-looking statements” as that term is defined
under federal securities laws. Investors are cautioned not to place undue
reliance on any forward-looking statements. In particular, our ability to
sell the Galileo Echo in the United States is dependent on FDA clearance,
and there is no guarantee whether or when the FDA will give that clearance.
Further risks are detailed in the Company’s filings with the Securities and
Exchange Commission. Immucor assumes no obligation to update any
forward-looking statements.
Immucor, Inc.
immucor